Home - Gastroenterology Advisor
While HIPAA rules protect health information of patients in hospitals and for physician visits, generally they do not protect the privacy or security of a patient’s health and wellness information when it is created accessed through or stored on personal cell …
Clinician Insights on How to Manage Semaglutide-Induced …
Sep 8, 2023 · Patients who receive treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide, may experience delayed gastric emptying due to the drug’s mechanism of action (MOA). 1 Symptoms may include nausea, vomiting, heartburn, pain, or bloating. 2 However, the symptoms of delayed gastric emptying resulting from GLP-1 receptor agonists may be similar to symptoms of ...
Long-Term Budesonide for Microscopic Colitis Is Effective …
Sep 20, 2023 · Budesonide efficaciously controls moderate to severe symptoms of microscopic colitis (MC) with a low risk for adverse effects from long-term use, according to study findings published in Inflammatory Bowel Diseases.. The inflammation that occurs in MC makes the colon less effective in absorbing liquid from the contents traveling through the bowel, often resulting in chronic diarrhea ...
Chronic Idiopathic Constipation: 10 Recommendations for …
Jun 9, 2023 · The American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG) have jointly developed a clinical practice guideline regarding the pharmacological management of patients with chronic idiopathic constipation (CIC), as published in the American Journal of Gastroenterology and Gastroenterology.. The guideline provides 10 evidence-based recommendations for ...
FDA Approves First Generic Liraglutide Once-Daily Injection
16 hours ago · HealthDay News — The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes.
Bariatric Surgery for Weight Loss: Gastric Sleeve vs Gastric Bypass
Nov 1, 2024 · References: Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022;18(12):1345-1356. doi: 10.1016/j.soard.2022.08.013 American Society for Metabolic and Bariatric Surgery.
Upadacitinib Improves Ulcerative Colitis Outcomes at 12 Months
1 day ago · HealthDay News — For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months compared with tofacitinib, according to a study published in the December issue of the American Journal of Gastroenterology.. Gursimran S. Kochhar, M.D., from the Allegheny Health Network in Pittsburgh, and colleagues conducted a retrospective cohort study to ...
Decompensated Cirrhosis: Poor Prognostic Communication Linked …
1 day ago · The study revealed that inadequate prognostic communication was associated with significantly worse outcomes, including higher symptom burden (β =7.14; 95% CI, 1.75-12.54; P =.01), anxiety (β =1.63; 95% CI, 0.49-2.78; P =.005), depression (β =1.50; 95% CI, 0.36-2.64; P =.010), and poorer HRQOL (β =-7.65; 95% CI, -12.02 to -3.27; P =.001). In contrast, frequent prognostic conversations were ...
Tremfya Approved for Moderate to Severe Ulcerative Colitis
Sep 23, 2024 · The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).. The approval was based on data from the phase 2b/3 QUASAR study (ClinicalTrials.gov Identifier: NCT04033445), which evaluated the safety and efficacy of guselkumab, an interleukin-23 antagonist, in patients with moderately ...
Upper GI Tract Disorders Treated With P-CABs: AGA Clinical …
Oct 25, 2024 · The American Gastroenterological Association (AGA) has released a clinical practice update for managing upper gastrointestinal (GI) tract disorders with potassium-competitive acid blockers (P-CABs).